PITTSBURGH, Aug. 5 CardiacAssist, Inc. announced that itreached a new seasonal high of over 50 cases performed in the month of July,despite the recent FDA 510(k) approval and follow on industry attention to theAbiomed Impella 2.5 device. The TandemHeart's higher flow rate, minimalcomplications and versatility in deployment to critically ill patients withouttraumatic surgery will continue to increase the device's presence in heartcenters in this country and abroad. When considering valve procedures andright heart cases that cannot be supported by the Impella 2.5, the TandemHeartis the only percutaneous solution. More than 125 hospitals worldwide now usethe TandemHeart System in the Cath Lab and/or Operating Room forextracorporeal circulatory support.
Four new centers have also added the TandemHeart System to their Cath Labor OR. The four new TandemHeart Centers of Excellence are:
"We're pleased to have such prestigious cardiac care facilities join ourCenters of Excellence that are now using the TandemHeart," said MichaelGarippa, President and CEO of CardiacAssist, Inc. "The adoption rate for thistechnology continues to increase, and our commercial experience with theTandemHeart will soon reach 1,500 cases.
The TandemHeart is fully reimbursed by Medicare under existing DRG codes.The device can be placed rapidly in the cath lab or operating room, providingeffective, reliable, temporary circulatory support. To date, the TandemHearthas been used in 28 countries by 125 different facilities by 200 differentphysicians.-- Baylor University Medical Center, Dallas, TX -- JFK Medical Center, Atlantis, FL -- Leesburg Regional Medical Center, Leesburg, FL -- Tufts-New England Medical Center, Boston, MA
SOURCE CardiacAssist, Inc.